Cost-competitive Bluetongue vaccine requires a lower dose

Gepubliceerd op
9 december 2016

Research on vaccine development for Bluetongue has resulted in completely safe replicating DISA vaccine without causing disease, enables DIVA, can be adapted for several serotypes, and can be safely used in combinations for different serotypes of Bluetongue. The recent study shows the cost-competiveness of the novel DISA vaccine as vaccination requires a low dose, and the optimal route by intramuscular vaccination is very suitable in mass vaccination campaigns.

Bluetongue (BT) is a disease of ruminants caused by bluetongue virus (BTV) transmitted by biting midges of the Culicoides genus. Outbreaks have been controlled successfully by vaccination, however, currently
available BT vaccines have several shortcomings, such as high costs for
inactivated vaccine, unsafety of live-attenuated vaccine, and lack of DIVA for both types of vaccines.

DISA vaccines
The DISA - Disabled Infectious Single Animal – vaccines, based on BTV without expression of dispensable non-structural NS3/NS3a protein,
protect sheep in a safe way against Bluetongue with lower doses than currently available vaccines. DISA vaccines are non-pathogenic replicating vaccines, do not cause viremia, enable to differentiate infected from vaccinated animals (DIVA) and are highly protective. Furthermore, DISA vaccines do not propagate in Culicoides midges, and thus uncontrolled spread of vaccine virus is blocked by lack of viremia as well as by the inability to replicate in insect vectors.

Low prtoective dose
The low protective dose for the prototype for serotype 8 of the DISA/DIVA vaccine platform also opens possibilities to easily formulate tailor-made multi-serotype cocktail vaccines, and ultimately broad protective DISA/DIVA vaccine for Bluetongue.